Welcome to LookChem.com Sign In|Join Free
  • or
[(1S,2R)-1-Benzyl-3-(4-cyano-2,2-dimethyl-butylamino)-2-hydroxy-propyl]-carbamic acid (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-yl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

288296-24-2

Post Buying Request

288296-24-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

288296-24-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 288296-24-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,2,9 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 288296-24:
(8*2)+(7*8)+(6*8)+(5*2)+(4*9)+(3*6)+(2*2)+(1*4)=192
192 % 10 = 2
So 288296-24-2 is a valid CAS Registry Number.

288296-24-2Downstream Products

288296-24-2Relevant academic research and scientific papers

Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains

Miller, John F.,Furfine, Eric S.,Hanlon, Mary H.,Hazen, Richard J.,Ray, John A.,Robinson, Laurence,Samano, Vicente,Spaltenstein, Andrew

, p. 959 - 963 (2007/10/03)

A novel series of P1′ chain-extended arylsufonamides was synthesiszed and evaluated for wild-type HIV protease inhibitory activity and in vitro antiviral activity against wild type virus and two protease inhibitor-resistant mutant viruses. All of the comp

Inhibitors of aspartyl protease

-

, (2008/06/13)

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 288296-24-2